They also suggested that this drug has the potential to eradicate AML blasts since they demonstrated that niclosamide kills AML CD34+CD38−stem-cells, while sparing normal bone marrow progenitors (Jin et al., 2010). This evidence concerns the gene CD34 and acute myeloid leukemia.